{"id":3181,"date":"2026-05-30T02:31:53","date_gmt":"2026-05-30T09:31:53","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=3181"},"modified":"2026-05-30T02:31:54","modified_gmt":"2026-05-30T09:31:54","slug":"fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/","title":{"rendered":"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">On May 29, the NMPA official website shows that FOSUNPHARMA\/Helsinn&#8217;s Class 5.1 imported new drug, AKYNZEO\u00ae concentrated solution for injection, obtains marketing approval in China for the prevention of chemotherapy\u2011induced nausea and vomiting.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AKYNZEO\u00ae intravenous injection (NEPA) is a fixed\u2011dose combination product containing 235 mg of fosnetupitant (equivalent to 260 mg of fosnetupitant chloride hydrochloride) and 0.25 mg of palonosetron (equivalent to 0.28 mg of palonosetron hydrochloride).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Among the two components, fosnetupitant (netupitant) is a neurokinin\u20111 (NK1) receptor antagonist, while palonosetron is a 5\u2011hydroxytryptamine type\u20113 (5\u2011HT3) receptor antagonist. The combination covers the entire phase (acute and delayed) of chemotherapy\u2011induced vomiting, improves the control rate of refractory vomiting through dual\u2011pathway blockade, and simplifies the clinical antiemetic regimen.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">According to Insight Database, this drug first received marketing approval in the United States in April 2018, in combination with dexamethasone for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy in adults. In December 2021, the drug also obtained approval in the European Union.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As early as October 2021, FOSUNPHARMA signed an exclusive license and distribution agreement with the Helsinn Group for a series of products. Under the agreement, effective from October 1, 2021, Helsinn grants FOSUNPHARMA\u2019s wholly\u2011owned Swiss subsidiary, Fosun Pharma AG, the exclusive right to distribute, promote and sell Aloxi\u00ae, Akynzeo\u00ae and Anamorelin in Mainland China, Hong Kong and Macau.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These products include two already approved products, Aloxi\u00ae (palonosetron hydrochloride) and Akynzeo\u00ae oral (netupitant and palonosetron hydrochloride), the intravenously administered NEPA (fosnetupitant and palonosetron hydrochloride) that receives approval in this announcement, and Anamorelin (a novel selective oral ghrelin receptor agonist) which has not yet been submitted for approval in China.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On May 29, the NMPA official website shows that FOSUNPHARMA\/Helsinn&#8217;s Class 5.1 imported new drug, AKYNZEO\u00ae concentrated solution for injection, obtains marketing approval in China for the prevention of chemotherapy\u2011induced nausea and vomiting. AKYNZEO\u00ae intravenous injection (NEPA) is a fixed\u2011dose combination product containing 235 mg of fosnetupitant (equivalent to 260 mg of fosnetupitant chloride hydrochloride) [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":3182,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-3181","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China<\/title>\n<meta name=\"description\" content=\"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-30T09:31:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-30T09:31:54+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/FOSUNPHARMA.png\" \/>\n\t<meta property=\"og:image:width\" content=\"420\" \/>\n\t<meta property=\"og:image:height\" content=\"310\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"FOSUNPHARMA\\\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing\",\"datePublished\":\"2026-05-30T09:31:53+00:00\",\"dateModified\":\"2026-05-30T09:31:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/\"},\"wordCount\":291,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/FOSUNPHARMA.png\",\"articleSection\":[\"Approved News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/\",\"name\":\"FOSUNPHARMA\\\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/FOSUNPHARMA.png\",\"datePublished\":\"2026-05-30T09:31:53+00:00\",\"dateModified\":\"2026-05-30T09:31:54+00:00\",\"description\":\"FOSUNPHARMA\\\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/FOSUNPHARMA.png\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/FOSUNPHARMA.png\",\"width\":420,\"height\":310},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FOSUNPHARMA\\\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China","description":"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/","og_locale":"en_US","og_type":"article","og_title":"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China","og_description":"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-05-30T09:31:53+00:00","article_modified_time":"2026-05-30T09:31:54+00:00","og_image":[{"width":420,"height":310,"url":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/FOSUNPHARMA.png","type":"image\/png"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing","datePublished":"2026-05-30T09:31:53+00:00","dateModified":"2026-05-30T09:31:54+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/"},"wordCount":291,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/FOSUNPHARMA.png","articleSection":["Approved News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/","url":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/","name":"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/FOSUNPHARMA.png","datePublished":"2026-05-30T09:31:53+00:00","dateModified":"2026-05-30T09:31:54+00:00","description":"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/FOSUNPHARMA.png","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/FOSUNPHARMA.png","width":420,"height":310},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/fosunpharma-helsinns-class-5-1-imported-new-drug-akynzeo-concentrated-solution-for-injection-approved-for-marketing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"FOSUNPHARMA\/Helsinn\u2019s Class 5.1 Imported New Drug AKYNZEO\u00ae\u00a0Concentrated Solution for Injection Approved for Marketing"}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=3181"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3181\/revisions"}],"predecessor-version":[{"id":3183,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3181\/revisions\/3183"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media\/3182"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=3181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=3181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=3181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}